<DOC>
	<DOCNO>NCT01390948</DOCNO>
	<brief_summary>This randomize , open-label , multicenter , 2-arm study investigate efficacy , safety , tolerability pharmacokinetics bevacizumab add postoperative radiotherapy concomitant adjuvant TMZ compare postoperative radiotherapy concomitant adjuvant TMZ alone paediatric participant newly diagnose histologically confirm World Health Organization ( WHO ) Grade III IV localize supratentorial infratentorial cerebellar peduncular high grade glioma ( HGG ) . Participants randomly assign one two treatment arm . Upon approval Health Authorities/Ethics Committees participate country , additional young participant cohort ( YPC ) ( child &gt; /= 6 month &lt; 3 year age progressive relapse metastatic localize , supra- infratentorial , non-brain stem WHO Grade III IV HGG ) include study . Children YPC receive bevacizumab TMZ without radiation therapy . The anticipated time study treatment 1 year .</brief_summary>
	<brief_title>A Study Bevacizumab ( Avastin ) Combination With Temozolomide ( TMZ ) Radiotherapy Paediatric Adolescent Participants With High-Grade Glioma</brief_title>
	<detailed_description />
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<criteria>Paediatric participant , age &gt; = 3 year &lt; 18 year Written inform consent obtain participant/parents legally acceptable representative Newly diagnose localise , supratentorial infratentorial cerebellar peduncular , WHO Grade III IV gliomas Local histological diagnosis confirm designated central reference neuropathologist Availability baseline magnetic resonance imaging ( MRI ) perform accord image guideline Able commence trial treatment 4 week cranial surgery later 6 week follow last major surgery Adequate bone marrow , coagulation , liver , renal function Young Participant Cohort Written inform consent obtain parent legal representative Age enrollment : &gt; = 6 month &lt; 3 year age Progressive relapse metastatic localise , supra infratentorial , nonbrain stem WHO Grade III IV glioma ( local pathology confirmation make either initial diagnosis relapse ) Availability baseline MRI perform accord image guideline Adequate organ function ( bone marrow , coagulation , liver , kidney ) Metastatic HGG define evidence neuraxis dissemination MRI positive cerebrospinal fluid ( CSF ) cytology WHOdefined Gliomatosis cerebri ( multifocal HGG ) Any disease condition contraindicates use study medication/treatment place patient unacceptable risk experience treatmentrelated complication Radiological evidence surgically related intracranial bleeding Prior diagnosis malignancy diseasefree 5 year Prior systemic anticancer therapy Previous cranial irradiation Young Participant Cohort WHOdefined Gliomatosis cerebri ( multifocal HGG ) Newly diagnose HGG age 3 year Relapsed HGG age 6 month age 3 year regardless age first onset Indication concomitant cranial irradiation , regardless age Any disease condition contraindicate use study medication/treatment place child unacceptable risk experience treatmentrelated complication Any specific contraindication MRI</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>